Author

John Szarejko

Observed name: John M. Szarejko

Institution: Children’s Mercy Research Institute

Observed institutions: Children’s Mercy Research Institute, University of Kansas Medical Center

ORCID: 0009-0004-3964-8354

Observed ORCID: 0009-0004-3964-8354

OpenAlex ID: A5044390702

248 Potent anti-tumor efficacy of B7-H3 CAR-T cells in H3G34 mutant diffuse hemispheric gliomas

2026 · Monika Yadav, David Akhavan, et al. · Journal for ImmunoTherapy of Cancer

IMMU-23 Locoregional B7-H3 CAR T Cell Therapy Elicits Potent Antitumor Immunity and Durable Responses in Preclinical Models of H3G34R/V-Mutant Diffuse Hemispheric Glioma: Rationale for Clinical Translation

2026 · Monika Yadav, David David Akhavan2, et al. · Neuro-Oncology

Potent antitumor preclinical efficacy of B7-H3 chimeric antigen receptor (CAR) T cells in H3G34-mutant, diffuse hemispheric glioma

2026 · David Akhavan, Monika Yadav, et al. · Neuro-Oncology

EXTH-116. Potent anti-tumor efficacy of B7-H3 CAR-T cells in H3G34-mutant Diffuse Hemispheric Gliomas

2025 · Monika Yadav, David Akhavan, et al. · Neuro-Oncology

IMMU-02. “Potent antitumor efficacy of anti-B7-H3 CAR T-cells in H3G34R/V mutated Diffuse Hemispheric Glioma”

2025 · Monika Yadav, Siddharth Subha, et al. · Neuro-Oncology Pediatrics

Exth-17. Therapeutic Efficacy of B7-h3 Car T Cells in Pediatric High-grade Gliomas With H3g34r/v Mutation

2024 · Monika Yadav, Siddharth Subham, et al. · Neuro-Oncology

Abstract 5557: Stem-like T cells maintain latent anticancer activity and underly therapy resistance

2024 · Fang Tao, Sara McElroy, et al. · Cancer Research

646. Development of a Novel Chimeric Antigen Receptor as a Therapy Against Solid Tumors

2016 · John M. Szarejko, Thomas M. Yankee, et al. · Molecular Therapy

Ikaros and aiolos undergo different post-transcriptional regulation in mice and humans (HEM4P.249)

2014 · Julie Mitchell, John Szarejko, et al. · The Journal of Immunology

Works count: 9

Citation count:

H-index:

I10-index: